[
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors",
    "summary": "In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $152.51, denoting a -0.44% change from the preceding trading day.",
    "url": "https://finnhub.io/api/news?id=9bfe89389c221cbdb77653f09cc22dfe884148def3eadc75e6ac5c29551ad104",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747950304,
      "headline": "Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors",
      "id": 134658446,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $152.51, denoting a -0.44% change from the preceding trading day.",
      "url": "https://finnhub.io/api/news?id=9bfe89389c221cbdb77653f09cc22dfe884148def3eadc75e6ac5c29551ad104"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson : showcases latest advancements in cancer innovation with more than 70 clinical and real-world studies at ASCO and EHA",
    "summary": "RARITAN, N.J., May 22, 2025 - Johnson & Johnson announced today promising new data from its hematologic malignancies and solid tumor portfolio and pipeline will be presented at the 2025 American...",
    "url": "https://finnhub.io/api/news?id=4001f7a23412a2875b76e64b073fa2dc1ee9d9f05f14b6039e0a7031da9c17f1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747934777,
      "headline": "Johnson & Johnson : showcases latest advancements in cancer innovation with more than 70 clinical and real-world studies at ASCO and EHA",
      "id": 134653582,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "RARITAN, N.J., May 22, 2025 - Johnson & Johnson announced today promising new data from its hematologic malignancies and solid tumor portfolio and pipeline will be presented at the 2025 American...",
      "url": "https://finnhub.io/api/news?id=4001f7a23412a2875b76e64b073fa2dc1ee9d9f05f14b6039e0a7031da9c17f1"
    }
  },
  {
    "ts": null,
    "headline": "JNJ Down 6% in 3 Months: How to Play the Stock Amid Various Challenges",
    "summary": "While J&J's Innovative Medicines segment is showing a growth trend, the MedTech unit's slowdown is a concern",
    "url": "https://finnhub.io/api/news?id=6c5c15163a3ac59f3e8e1f7dad6a21d50e719dc5a787a58b2ede1656a952c860",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747919220,
      "headline": "JNJ Down 6% in 3 Months: How to Play the Stock Amid Various Challenges",
      "id": 134658447,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "While J&J's Innovative Medicines segment is showing a growth trend, the MedTech unit's slowdown is a concern",
      "url": "https://finnhub.io/api/news?id=6c5c15163a3ac59f3e8e1f7dad6a21d50e719dc5a787a58b2ede1656a952c860"
    }
  },
  {
    "ts": null,
    "headline": "CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success",
    "summary": "CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.",
    "url": "https://finnhub.io/api/news?id=e83f7945e0bc79c15190095fcd18216a5bbb4f6e3dd5d3bfd5f228a311692fe0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747917960,
      "headline": "CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success",
      "id": 134658448,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.",
      "url": "https://finnhub.io/api/news?id=e83f7945e0bc79c15190095fcd18216a5bbb4f6e3dd5d3bfd5f228a311692fe0"
    }
  },
  {
    "ts": null,
    "headline": "BNY Mellon Global Equity Income Fund Q1 2025 Commentary",
    "summary": "BNY Mellon Global Equity Income Fund Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=21122177dcf301c8a85b28db74c633dac60cf5d385c12b4c38dab38f5f17dfc1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747917060,
      "headline": "BNY Mellon Global Equity Income Fund Q1 2025 Commentary",
      "id": 134651954,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=21122177dcf301c8a85b28db74c633dac60cf5d385c12b4c38dab38f5f17dfc1"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Undervalued In Light Of Key Risks",
    "summary": "Merck: Undervalued In Light Of Key Risks",
    "url": "https://finnhub.io/api/news?id=2cf83a06c667d933b5230efc127d32ca765138c4065e6106fe71e2e81afcac58",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747917000,
      "headline": "Merck: Undervalued In Light Of Key Risks",
      "id": 134651888,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=2cf83a06c667d933b5230efc127d32ca765138c4065e6106fe71e2e81afcac58"
    }
  },
  {
    "ts": null,
    "headline": "BNY Mellon Dynamic Value Fund Q1 2025 Commentary",
    "summary": "BNY Mellon Dynamic Value Fund (Class A at NAV) returned 2.63% during the first quarter of 2025.",
    "url": "https://finnhub.io/api/news?id=dffb1eabb98f7e0a46b4ce50bd2a55265d5a39faf2464cfe0fc9beea9f4d2017",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747912440,
      "headline": "BNY Mellon Dynamic Value Fund Q1 2025 Commentary",
      "id": 134651348,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160994971/image_2160994971.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "BNY Mellon Dynamic Value Fund (Class A at NAV) returned 2.63% during the first quarter of 2025.",
      "url": "https://finnhub.io/api/news?id=dffb1eabb98f7e0a46b4ce50bd2a55265d5a39faf2464cfe0fc9beea9f4d2017"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson MedTech introduces ultrasound catheter for cardiac ablation",
    "summary": "Featuring an 88-element phased linear array, the catheter claims to deliver detailed visualisation.",
    "url": "https://finnhub.io/api/news?id=23224b483a4d8950b22c2de2071c1f18abd69d9f0cd3c8a4ae719fb1a82e92d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747905601,
      "headline": "Johnson & Johnson MedTech introduces ultrasound catheter for cardiac ablation",
      "id": 134647933,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Featuring an 88-element phased linear array, the catheter claims to deliver detailed visualisation.",
      "url": "https://finnhub.io/api/news?id=23224b483a4d8950b22c2de2071c1f18abd69d9f0cd3c8a4ae719fb1a82e92d8"
    }
  }
]